Evaluation of TLR9 expression on PBMCs and CpG ODN-TLR9 ligation on IFN-α production in SLE patients

References

• Crispín JC, Liossis SNC, Kis-Toth K, et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med 2010;16:47–57.
   PubMed Web of Science ®Google Scholar
• Bootsma H, Spronk P, Hummel E, et al. Anti-double stranded DNA antibodies in systemic lupus erythematosus: detection and clinical relevance of IgM-class antibodies. Scand J Rheumatol 1996;25:352–359.
   PubMed Web of Science ®Google Scholar
• Notman D, Kurata N, Tan EM. Profiles of antinuclear antibodies in systemic rheumatic diseases. Ann Intern Med 1975;83:464–469.
   PubMed Web of Science ®Google Scholar
• Anaya JM, Shoenfeld Y, Cervera R. Systemic lupus erythematosus 2014. Autoimmune Dis 2014;2014. doi: 10.1155/2014/274323.
   PubMedGoogle Scholar
• Hoffmann MH, Trembleau S, Muller S, Steiner G. Nucleic acid-associated autoantigens: pathogenic involvement and therapeutic potential. J Autoimmun 2010;34:J178–J206.
   PubMed Web of Science ®Google Scholar
• Kontaki E, Boumpas DT. Innate immunity in systemic lupus erythematosus: sensing endogenous nucleic acids. J Autoimmun 2010;35:206–211.
   PubMed Web of Science ®Google Scholar
• Blasius AL, Beutler B. Intracellular toll-like receptors. Immunity 2010;32:305–315.
   PubMed Web of Science ®Google Scholar
• Guggino G, Giardina AR, Ciccia F, Triolo G, Dieli F, Sireci G. Are toll-like receptors and decoy receptors involved in the immunopathogenesis of systemic lupus erythematosus and lupus-like syndromes? Clin Dev Immunol 2012;2012:135932. doi: 10.1155/2012/135932.
   PubMedGoogle Scholar
• Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004;5:987–995.
   PubMed Web of Science ®Google Scholar
• Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006;6:823–835.
   PubMed Web of Science ®Google Scholar
• Barrat FJ, Meeker T, Gregorio J, et al. Nucleic acids of mammalian origin can act as endogenous ligands for toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005;202:1131–1139.
   PubMed Web of Science ®Google Scholar
• Dorner M, Brandt S, Tinguely M, et al. Plasma cell toll‐like receptor (TLR) expression differs from that of B cells, and plasma cell TLR triggering enhances immunoglobulin production. Immunology 2009;128:573–579.
   PubMed Web of Science ®Google Scholar
• Jarrossay D, Napolitani G, Colonna M, et al. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol 2001;31:3388–3393.
   PubMed Web of Science ®Google Scholar
• Kadowaki N, Ho S, Antonenko S, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001;194:863–870.
   PubMed Web of Science ®Google Scholar
• Santiago-Raber ML, Baudino L, Izui S. Emerging roles of TLR7 and TLR9 in murine SLE. J Autoimmun 2009;33:231–238.
   PubMed Web of Science ®Google Scholar
• Horton CG, Pan Zj, Farris AD. Targeting toll-like receptors for treatment of SLE. Mediators Inflamm 2010;2010.
   PubMed Web of Science ®Google Scholar
• Frieri M. Mechanisms of disease for the clinician: systemic lupus erythematosus. Ann Allergy Asthma Immunol 2013;110:228–232.
   PubMed Web of Science ®Google Scholar
• Tian J, Avalos AM, Mao SY, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE . Nat Immunol 2007;8:487–496.
   PubMed Web of Science ®Google Scholar
• Gilliet M, Cao W, Liu YJ. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol 2008;8:594–606.
   PubMed Web of Science ®Google Scholar
• Kwok SK, Lee JY, Park SH, et al. Dysfunctional interferon-α production by peripheral plasmacytoid dendritic cells upon toll-like receptor-9 stimulation in patients with systemic lupus erythematosus. Arthritis Res Ther 2008;10:1.
   Web of Science ®Google Scholar
• Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992;35:630–640.
   PubMed Web of Science ®Google Scholar
• Krug A, Rothenfusser S, Hornung V, et al. Identification of CpG oligonucleotide sequences with high induction of IFN‐α/β in plasmacytoid dendritic cells. Eur J Immunol 2001;31:2154–2163.
   PubMed Web of Science ®Google Scholar
• Blomberg S, Eloranta ML, Magnusson M, et al. Expression of the markers BDCA‐2 and BDCA‐4 and production of interferon‐α by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Rheum 2003;48:2524–2532.
   PubMed Web of Science ®Google Scholar
• Vallin H, Blomberg Alm S, Cederblad GB, Rönnblom L. Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-) production acting on leucocytes resembling immature dendritic cells. Clin Exp Immunol 1999;115:196–202.
   PubMed Web of Science ®Google Scholar
• Lourenco EV, Cava AL. Cytokines in systemic lupus erythematosus. Curr Mol Med 2009;9:242–254.
   PubMed Web of Science ®Google Scholar
• Kim WU, Sreih A, Bucala R. Toll-like receptors in systemic lupus erythematosus; prospects for therapeutic intervention. Autoimmun Rev 2009;8:204–208.
   PubMed Web of Science ®Google Scholar
• Mortezagholi S, Babaloo Rahimzadeh Z, Ghaedi P, et al. Evaluation of PBMC distribution and TLR9 expression in patients with systemic lupus erythematosus. Iran J Allergy Asthma Immunol 2016;15:229–236.
   PubMed Web of Science ®Google Scholar
• Migita K, Miyashita T, Maeda Y, et al. Toll-like receptor expression in lupus peripheral blood mononuclear cells. J Rheumatol 2007;34:493–500.
   PubMed Web of Science ®Google Scholar
• Rönnblom L, Pascual V. The innate immune system in SLE: type I interferons and dendritic cells. Lupus 2008;17:394–399.
   PubMed Web of Science ®Google Scholar
• Farkas L, Beiske K, Lund-Johansen F, et al. Plasmacytoid dendritic cells (natural interferon-α/β-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 2001;159:237–243.
   PubMed Web of Science ®Google Scholar
• Nakano S, Morimoto S, Suzuki J, et al. Role of pathogenic auto-antibody production by toll-like receptor 9 of B cells in active systemic lupus erythematosus. Rheumatology 2008;47:145–149.
   PubMed Web of Science ®Google Scholar
• Ghaly NR, Kotb NA, Nagy HM, Rageh ESM. Toll-like receptor 9 in systemic lupus erythematosus, impact on glucocorticoid treatment. J Dermatolog Treat 2013;24:411–417.
   PubMed Web of Science ®Google Scholar
• Papadimitraki ED, Choulaki C, Koutala E, et al. Expansion of toll‐like receptor 9–expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis Rheum 2006;54:3601–3611.
   PubMed Web of Science ®Google Scholar
• Hawker G, Gabriel S, Bombardier C, et al. A reliability study of SLEDAI: a disease activity index for systemic lupus erythematosus. J Rheumatol 1993;20:657–660.
   PubMed Web of Science ®Google Scholar
• Brunner HI, Feldman BM, Bombardier C, Silverman ED. Sensitivity of the systemic lupus erythematosus disease activity index, British Isles lupus assessment group index, and systemic lupus activity measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus. Arthritis Rheum 1999;42:1354–1360.
   PubMed Web of Science ®Google Scholar
• Kelly-Worden M, Hammer L, Gebhard R, et al. Anti-nuclear antibodies positive serum from systemic lupus erythematosus patients promotes cardiovascular manifestations and the presence of human antibody in the brain. J Pharm Bioallied Sci 2014;6:198.
   PubMedGoogle Scholar
• Wermeling F, Lind SM, Jordö ED, et al. Invariant NKT cells limit activation of autoreactive CD1d-positive B cells. J Exp Med 2010;207:943–952.
   PubMed Web of Science ®Google Scholar
• Yung S, Chan TM. Anti-DNA antibodies in the pathogenesis of lupus nephritis – the emerging mechanisms. Autoimmun Rev 2008;7:317–321.
   PubMed Web of Science ®Google Scholar
• Christensen SR, Kashgarian M, Alexopoulou L, et al. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med 2005;202:321–331.
   PubMed Web of Science ®Google Scholar
• Leadbetter EA, Rifkin IR, Hohlbaum AM, et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and toll-like receptors. Nature 2002;416:603–607.
   PubMed Web of Science ®Google Scholar
• Christensen SR, Shlomchik MJ. Regulation of lupus-related autoantibody production and clinical disease by toll-like receptors. Semin Immunol. 2007;19:11–23. doi: 10.1016/j.smim.2006.12.005.
   Google Scholar
• Mok C, Lau C. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 2003;56:481–490.
   PubMed Web of Science ®Google Scholar
• Means TK, Latz E, Hayashi F, et al. Human lupus autoantibody–DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Investig 2005;115:407–417.
   PubMed Web of Science ®Google Scholar
• Seillet C, Laffont S, Trémollières F, et al. The TLR-mediated response of plasmacytoid dendritic cells is positively regulated by estradiol in vivo through cell-intrinsic estrogen receptor α signaling. Blood 2012;119:454–464.
   PubMed Web of Science ®Google Scholar
• Malleson PN, Sailer M, Mackinnon MJ. Usefulness of antinuclear antibody testing to screen for rheumatic diseases. Arch Dis Child 1997;77:299–304.
   PubMed Web of Science ®Google Scholar
• Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003;21:335–376.
   PubMed Web of Science ®Google Scholar
• Verthelyi D, Petri M, Ylamus M, Klinman D. Disassociation of sex hormone levels and cytokine production in SLE patients. Lupus 2001;10:352–358.
   PubMed Web of Science ®Google Scholar
• Hagiwara E, Abbasi F, Mor G, et al. Phenotype and frequency of cells secreting IL-2, IL-4, IL-6, IL-10, IFN and TNF-α in human peripheral blood. Cytokine 1995;7:815–822.
   PubMed Web of Science ®Google Scholar
• Verthelyi D, Klinman D. Sex hormone levels correlate with the activity of cytokine-secreting cells in vivo. Immunology 2000;100:384–390.
   PubMed Web of Science ®Google Scholar
• Richez C, Blanco P, Rifkin I, et al. Role for toll-like receptors in autoimmune disease: the example of systemic lupus erythematosus. Joint Bone Spine 2011;78:124–130.
   PubMed Web of Science ®Google Scholar
• Willis R, Seif A, McGwin G, et al. Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort. Lupus 2012;21:830–835.
   PubMed Web of Science ®Google Scholar
• Tan TC, Fang H, Magder LS, Petri MA. Differences between male and female systemic lupus erythematosus in a multiethnic population. J Rheumatol 2012;39:759–769.
   PubMed Web of Science ®Google Scholar
• Klonowska-Szymczyk A, Wolska A, Robak T, et al. Expression of toll-like receptors 3, 7, and 9 in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Mediators Inflamma 2014;2014.
   PubMed Web of Science ®Google Scholar
• Feng JB, Ni JD, Yao X, et al. Gender and age influence on clinical and laboratory features in Chinese patients with systemic lupus erythematosus: 1,790 cases. Rheumatol Int 2010;30:1017–1023.
   PubMed Web of Science ®Google Scholar